Leerink Partnrs Weighs in on Myriad Genetics Q3 Earnings

Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) - Research analysts at Leerink Partnrs upped their Q3 2025 earnings per share estimates for Myriad Genetics in a research note issued on Monday, April 21st. Leerink Partnrs analyst P. Souda now anticipates that the company will earn ($0.05) per share for the quarter, up from their prior estimate of ($0.06). The consensus estimate for Myriad Genetics' current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for Myriad Genetics' FY2025 earnings at ($0.31) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.14) EPS.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.12). Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. The firm had revenue of $210.60 million for the quarter, compared to the consensus estimate of $210.35 million. During the same quarter in the prior year, the business posted ($0.12) earnings per share.

Several other equities research analysts also recently commented on MYGN. Piper Sandler upgraded Myriad Genetics from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $11.50 to $12.50 in a report on Wednesday, March 12th. UBS Group reduced their price target on shares of Myriad Genetics from $18.00 to $16.00 and set a "neutral" rating for the company in a research note on Tuesday, February 25th. Bank of America lowered their price objective on shares of Myriad Genetics from $13.00 to $11.00 and set an "underperform" rating on the stock in a research report on Monday, March 3rd. Scotiabank cut their target price on shares of Myriad Genetics from $24.00 to $20.00 and set a "sector outperform" rating for the company in a research report on Tuesday, April 1st. Finally, The Goldman Sachs Group lowered their price target on Myriad Genetics from $18.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $20.61.

Myriad Genetics Stock Down 0.7 %

MYGN traded down $0.06 during trading on Wednesday, hitting $7.37. 782,704 shares of the company's stock traded hands, compared to its average volume of 946,345. Myriad Genetics has a 12-month low of $7.16 and a 12-month high of $29.30. The company's 50 day simple moving average is $9.55 and its two-hundred day simple moving average is $13.62. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $678.84 million, a price-to-earnings ratio of -5.67 and a beta of 1.87.

Hedge Funds Weigh In On Myriad Genetics

A number of hedge funds have recently made changes to their positions in MYGN. Blue Trust Inc. boosted its stake in Myriad Genetics by 57.0% in the 1st quarter. Blue Trust Inc. now owns 14,367 shares of the company's stock worth $127,000 after purchasing an additional 5,214 shares during the period. M.E. Allison & CO. Inc. purchased a new position in shares of Myriad Genetics in the first quarter worth $93,000. GAMMA Investing LLC boosted its position in shares of Myriad Genetics by 520.8% during the first quarter. GAMMA Investing LLC now owns 4,470 shares of the company's stock worth $40,000 after acquiring an additional 3,750 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Myriad Genetics by 43.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 285,229 shares of the company's stock worth $3,910,000 after acquiring an additional 86,973 shares during the last quarter. Finally, Voloridge Investment Management LLC bought a new stake in Myriad Genetics in the 4th quarter valued at $1,635,000. Institutional investors own 99.02% of the company's stock.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.